The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies program for Caprelsa, a thyroid cancer medication ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE